The state of California currently has 38 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Ketamine for MS Fatigue
NCT06064162
Recruiting
The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue. The investigator proposes a prospective, crossover, randomized, placebo-controlled study to assess the efficacy and safety of low, single dose Ketamine, to assess its efficacy and safety in patients with MS-related fatigue.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2024
Locations: Alta Bates Summit Medical Center, Berkeley, California
Conditions: Multiple Sclerosis
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877
Recruiting
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part... Read More
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
05/31/2024
Locations: UC San Diego Health, San Diego, California
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
NCT04002934
Recruiting
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigatio... Read More
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/29/2024
Locations: Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Fullerton Neuro and Headache Ctr, Fullerton, California +1 locations
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
NCT04933552
Recruiting
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
Gender:
Female
Ages:
All
Trial Updated:
05/14/2024
Locations: Novartis Investigative Site, La Jolla, California
Conditions: Multiple Sclerosis
Register for Updates
Kesimpta (Ofatumumab) Pregnancy Registry
NCT05634967
Recruiting
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Novartis Investigative Site, La Jolla, California
Conditions: Multiple Sclerosis, Pregnancy
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/07/2024
Locations: The Research and Education Inst. of Alta Bates Summit Med. Grp, Berkeley, California +5 locations
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
NCT05122559
Recruiting
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Gender:
All
Ages:
Between 40 years and 70 years
Trial Updated:
05/06/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Register for Updates
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
NCT06083753
Recruiting
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/30/2024
Locations: Sutter East Bay Medical Foundation, Berkeley, California
Conditions: Relapsing Remitting Multiple Sclerosis
Register for Updates
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
NCT06138132
Recruiting
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/26/2024
Locations: Stanford Multiple Sclerosis Center, Palo Alto, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Register for Updates
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
NCT04458051
Recruiting
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/24/2024
Locations: UC San Diego ACTRI Site Number : 8400101, La Jolla, California +6 locations
Conditions: Primary Progressive Multiple Sclerosis
Register for Updates
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/22/2024
Locations: Novartis Investigative Site, Los Angeles, California +1 locations
Conditions: Multiple Sclerosis
Register for Updates